Key PointsThe Nasdaq has sold off in the last month while the Dow has gained.

After the Midterm Rally, the Dow Is on Track to Beat the Nasdaq for the First Time Since 2022. Here's What History Says Could Come Next.

Key PointsPfizer and Bristol Myers Squibb have faced similar challenges, and both are slowly overcoming their obstacles.

3 High-Yield Healthcare Stocks to Buy With $1,000 and Hold Through Any Market

Key PointsPfizer raised 2026 revenue guidance to $62 billion to $64 billion.

Pfizer: 3 Key Takeaways for Long-Term Investors

Pfizer Inc. announced that its Board of Directors unanimously elected Cecile Guegan to serve as Chief Financial Officer, Executive Vice President of the Company, effective November 1, 2026. Ms. Guegan, 55, was previously appointed as the Company’s Interim Chief Financial Of

Pfizer Inc. Appoints Cecile Guegan as Chief Financial Officer

Key PointsRevenue was flat at $16.6 billion, with COVID and Prevnar sales falling while Eliquis, Padcev, Vyndaqel, Nurtec, and Lorbrena grew.

Pfizer's Eliquis Price Gains Cover COVID Drop: Rapid Earnings Reaction

Pfizer Inc. reported its financial results for the third quarter of 2026, with revenues of $16.6 Billion, which was relatively flat year-over-year operationally. Excluding contributions from Comirnaty and Paxlovid, revenues grew 7% operationally. The company reported third-quarte

Pfizer Inc. Reports Third-Quarter 2026 Results and Raises Full-Year Guidance

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Pfizer Inc. News